Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Recurrence × relatlimab × Clear all

Phase

Status

Terminated 1 Recruiting 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Melanoma 7 Carcinoma, Non-Small-Cell Lung 2 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Nasopharyngeal Carcinoma 1 Muscle Invasive Bladder Urothelial Carcinoma 1 Locally Advanced Melanoma 1 Leukemia, Myeloid, Acute 1 Glioblastoma 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1 Carcinoma, Merkel Cell 1 Carcinoma, Hepatocellular 1 Carcinoma, Basal Cell 1

Interventions

venetoclax 19 Cyclophosphamide 17 pembrolizumab 15 Dexamethasone 15 Cytarabine 12 fludarabine 11 Azacitidine 11 Gemcitabine 9 pomalidomide 8 glofitamab 7 Rituximab 7 Lenalidomide 7 Carboplatin 7 selinexor 6 Temozolomide 6 Granulocyte Colony-Stimulating Factor 6 fludarabine phosphate 5 daratumumab 5 Paclitaxel 5 Oxaliplatin 5 Nivolumab 5 Injections 5 Cisplatin 5 zanubrutinib 4 ruxolitinib 4 obinutuzumab 4 carfilzomib 4 Surgical Procedures, Operative 4 Immunotherapy, Adoptive 4 Decitabine 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04913922 2022-11-08

AARON

Ludwig-Maximilians - University of Munich

Phase 2 Recruiting

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡